SENSEX
NIFTY
GOLD
USD/INR

Weather

image 15    C

Global Business News

The Economic Times

Global Business / The Economic Times

details

Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out

Novo Nordisk shares have fallen sharply. Their new obesity drug, CagriSema, did not meet expectations in trials. This setback affects future sales and market position. Eli Lilly's shares saw a rise. Investors are watching competition in the weight-loss drug market closely. Novo's stock is back to levels seen before Wegovy's success.

23 Feb 2026 10:41 pm